Standard

DNA damage response and resistance of cancer stem cells. / Abad, Etna; Graifer, Dmitry; Lyakhovich, Alex.

в: Cancer Letters, Том 474, 01.04.2020, стр. 106-117.

Результаты исследований: Научные публикации в периодических изданияхобзорная статьяРецензирование

Harvard

Abad, E, Graifer, D & Lyakhovich, A 2020, 'DNA damage response and resistance of cancer stem cells', Cancer Letters, Том. 474, стр. 106-117. https://doi.org/10.1016/j.canlet.2020.01.008

APA

Vancouver

Abad E, Graifer D, Lyakhovich A. DNA damage response and resistance of cancer stem cells. Cancer Letters. 2020 апр. 1;474:106-117. doi: 10.1016/j.canlet.2020.01.008

Author

Abad, Etna ; Graifer, Dmitry ; Lyakhovich, Alex. / DNA damage response and resistance of cancer stem cells. в: Cancer Letters. 2020 ; Том 474. стр. 106-117.

BibTeX

@article{a436a5e871294367a4f74862e31d73f0,
title = "DNA damage response and resistance of cancer stem cells",
abstract = "The cancer stem cell (CSC) model defines tumors as hierarchically organized entities, containing a small population of tumorigenic CSC, or tumour-initiating cells, placed at the apex of this hierarchy. These cells may share common qualities with chemo- and radio-resistant cancer cells and contribute to self-renewal activities resulting in tumour formation, maintenance, growth and metastasis. Yet, it remains obscure what self-defense mechanisms are utilized by these cells against the chemotherapeutic drugs or radiotherapy. Recently, attention has been focused on the pivotal role of the DNA damage response (DDR) in tumorigenesis. In line with this note, an increased DDR that prevents CSC and chemoresistant cells from genotoxic pressure of chemotherapeutic drugs or radiation may be responsible for cancer metastasis. In this review, we focus on the current knowledge concerning the role of DDR in CSC and resistant cancer cells and describe the existing opportunities of re-sensitizing such cells to modulate therapeutic treatment effects.",
keywords = "Chemoresistance, DNA damage and repair, Radioresistance, Tumour-initiating cells, INITIATING CELLS, INCREASED EXPRESSION, DRUG-RESISTANCE, REPAIR PATHWAYS, EPITHELIAL-MESENCHYMAL TRANSITION, BREAST-CANCER, RADIATION-RESISTANCE, HOMOLOGOUS-RECOMBINATION, ESOPHAGEAL CANCER, CHEMOTHERAPY RESISTANCE",
author = "Etna Abad and Dmitry Graifer and Alex Lyakhovich",
note = "Copyright {\textcopyright} 2020 Elsevier B.V. All rights reserved.",
year = "2020",
month = apr,
day = "1",
doi = "10.1016/j.canlet.2020.01.008",
language = "English",
volume = "474",
pages = "106--117",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - DNA damage response and resistance of cancer stem cells

AU - Abad, Etna

AU - Graifer, Dmitry

AU - Lyakhovich, Alex

N1 - Copyright © 2020 Elsevier B.V. All rights reserved.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - The cancer stem cell (CSC) model defines tumors as hierarchically organized entities, containing a small population of tumorigenic CSC, or tumour-initiating cells, placed at the apex of this hierarchy. These cells may share common qualities with chemo- and radio-resistant cancer cells and contribute to self-renewal activities resulting in tumour formation, maintenance, growth and metastasis. Yet, it remains obscure what self-defense mechanisms are utilized by these cells against the chemotherapeutic drugs or radiotherapy. Recently, attention has been focused on the pivotal role of the DNA damage response (DDR) in tumorigenesis. In line with this note, an increased DDR that prevents CSC and chemoresistant cells from genotoxic pressure of chemotherapeutic drugs or radiation may be responsible for cancer metastasis. In this review, we focus on the current knowledge concerning the role of DDR in CSC and resistant cancer cells and describe the existing opportunities of re-sensitizing such cells to modulate therapeutic treatment effects.

AB - The cancer stem cell (CSC) model defines tumors as hierarchically organized entities, containing a small population of tumorigenic CSC, or tumour-initiating cells, placed at the apex of this hierarchy. These cells may share common qualities with chemo- and radio-resistant cancer cells and contribute to self-renewal activities resulting in tumour formation, maintenance, growth and metastasis. Yet, it remains obscure what self-defense mechanisms are utilized by these cells against the chemotherapeutic drugs or radiotherapy. Recently, attention has been focused on the pivotal role of the DNA damage response (DDR) in tumorigenesis. In line with this note, an increased DDR that prevents CSC and chemoresistant cells from genotoxic pressure of chemotherapeutic drugs or radiation may be responsible for cancer metastasis. In this review, we focus on the current knowledge concerning the role of DDR in CSC and resistant cancer cells and describe the existing opportunities of re-sensitizing such cells to modulate therapeutic treatment effects.

KW - Chemoresistance

KW - DNA damage and repair

KW - Radioresistance

KW - Tumour-initiating cells

KW - INITIATING CELLS

KW - INCREASED EXPRESSION

KW - DRUG-RESISTANCE

KW - REPAIR PATHWAYS

KW - EPITHELIAL-MESENCHYMAL TRANSITION

KW - BREAST-CANCER

KW - RADIATION-RESISTANCE

KW - HOMOLOGOUS-RECOMBINATION

KW - ESOPHAGEAL CANCER

KW - CHEMOTHERAPY RESISTANCE

UR - http://www.scopus.com/inward/record.url?scp=85078590049&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2020.01.008

DO - 10.1016/j.canlet.2020.01.008

M3 - Review article

C2 - 31968219

AN - SCOPUS:85078590049

VL - 474

SP - 106

EP - 117

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -

ID: 23264658